德国拜耳利伐沙班效果怎么样？

(Rivaroxaban) is a drug jointly developed by Bayer Pharma of Germany and Johnson & Johnson of the United States. It works by selectively acting on the coagulation factor Xa. It is commonly used in the prevention and treatment of thrombosis. It not only has good pharmacodynamics and pharmacokinetic characteristics, but also has good effectiveness and safety, and is cost-effective. In clinical applications, it can be combined with the patient's physiological functions and medication status for medication monitoring.

Compared with other anticoagulants, rivaroxaban and heparin analogues can reduce the risk of thrombosis through anticoagulation, but may increase the risk of bleeding. A previous systematic study using meta-analysis showed that the factor Xa inhibitor rivaroxaban has similar effects and safety to low-molecular-weight heparin after total hip and total knee arthroplasty, but rivaroxaban has the disadvantage of slightly increasing the risk of bleeding.

The Einstein-PE study is a randomized, open-label, event-driven, non-inferiority phase III clinical study designed to compare the efficacy and safety of rivaroxaban monotherapy in the treatment of venous thromboembolism with enoxaparin standard treatment of venous thromboembolism. Studies have shown that the efficacy and safety of rivaroxaban alone in the treatment of venous thromboembolism is equivalent to that of standard treatment. There was no significant difference in the incidence of recurrent symptomatic venous thromboembolism between the rivaroxaban group and the enoxaparin group; there was no significant difference in the incidence of clinically relevant bleeding events between the two groups; the relative risk of major bleeding was significantly reduced by 51% in the rivaroxaban group, and the rates of other adverse events were similar between the two groups.

Bayer Group has a strong asset base and is one of the world's top 500 companies. In 2005, it raised US$1.5 billion in funds to mainly develop the Chinese pharmaceutical market. Bayer has a long history, has a strong international brand reputation, and implements the corporate mission of "technology creates a better life". It is one of the top ten pharmaceutical companies in the world. It is produced by Bayer in Germany and is suitable for the treatment of venous thrombosis. Patients in need can contact the Medical Companion Brigade to obtain it.

Recommended hot articles: /newsDetail/86336.html